Gene Expression Panels Less Cost-Effective in Real-World Settings
...
Already a member? Log in here
Genetic Profiling: Study Casts Doubt on Cost-Effectiveness of Leading Breast Cancer Recurrence Assay
From - Laboratory Industry Report
Among the many genetic profiling assays entering the commercial market, few have been more successful than Genomic Heath's Oncotype DX, which is now covered by most of …
Already a member? Log in here
Innovation: AMP Issues New Guidelines for NGS Pipeline Validation
From - National Intelligence Report
Molecular next-generation sequencing (NGS) tests have spurred tremendous growth in the lab industry. But as often happens with innovation, NGS technology may be…
Already a member? Log in here
FDA’s Two Big Moves on NGS-Based Tumor Panels May Offer Clues for Alternative Pathways for LDT Approval
...
Already a member? Log in here
New Lawsuit Tests Limits of Medical Malpractice in Age of Precision Medicine
From - National Intelligence Report
One patient claims it is and wants $1.8 million in damages because she never got it…
Already a member? Log in here